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THALIDOMIDE
Unlocking a dark past
A transcription factor called SALL4 could be the missing link between
thalidomide and the limb defects caused by the drug.
FERNANDO RODRI´GUEZ-PE´REZ AND MICHAEL RAPE
O
n October 2, 1957 the German phar-
maceutical company Gru¨nenthal intro-
duced Contergan, a new over-the-
counter drug to treat insomnia. Gru¨nenthal
researchers had originally obtained its active
compound, thalidomide, by heating a commer-
cially available chemical (phthaloyl isoglutamine)
in an attempt to develop a new antibiotic
(Brynner and Stephens, 2001). However, after
failing to observe any antibiotic activity, Gru¨nen-
thal searched for other possible applications and
found that thalidomide induced sleep in about
60% of treated patients. Although this sleep-
inducing effect was not observed in mice and
rats, the rodents tolerated very high levels of the
drug, prompting Gru¨nenthal to proclaim that
the new sedative was completely safe and could
even be taken by pregnant women for morning
sickness.
This turned out to be a dramatic mistake:
repeated use of thalidomide induced peripheral
neuropathy, and if taken during the first trimes-
ter of pregnancy, even a single dose triggered
birth defects referred to as phocomelia, a reduc-
tion or absence of limbs. When Contergan was
finally removed from the shelves in 1961, it may
have caused birth defects in nearly 10,000
individuals, approximately 5,000 of whom sur-
vived childhood. Yet, exactly how thalidomide
causes limb deformations in humans, while also
sparing rodents, has remained a mystery
(Lenz, 1988).
Despite its dark past, thalidomide and its
derivatives, lenalidomide and pomalidomide,
found their way back into the clinic. Commonly
referred to as immunomodulatory drugs, these
compounds are used as first-line treatment for
multiple myeloma, del(5q)-MDS and leprosy.
Similar to the role of thalidomide in causing birth
defects, the biological mechanism underlying its
therapeutic benefits had been unknown until
2010, when the primary binding target of thalid-
omide was identified as a protein called cere-
blon (CRBN; Ito et al., 2010). This protein forms
a complex called CUL4CRBN (Figure 1), which is
known to be an E3 ubiquitin ligase.
In multiple myeloma, rather than inhibiting
this ligase, thalidomide recruits two zinc-finger
transcription factors to the complex, which
results in these transcription factors being ubiq-
uitylated and subsequently degraded by protea-
somes (Lu et al., 2014). A similar mechanism
operates in del(5q)-MDS, where the drugs trig-
ger the degradation of a kinase called CK1a
(Kro¨nke et al., 2015; Petzold et al., 2016).
However, neither of these neo-substrates shed
light on the teratogenic effects of thalidomide,
and the question of how the drug interfered
with limb development remained unanswered.
Now, in eLife, Eric Fischer and colleagues at the
Dana-Farber Cancer Institute, Harvard Medical
School and Brigham and Women’s Hospital –
including Katherine Donovan as first author –
report results that shed light onto this decades-
old question (Donovan et al., 2018).
Human embryonic stem cells are powerful
models in which to study the regulatory circuits
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of human development. Donovan et al. used
quantitative mass spectrometry in such stem
cells to identify proteins that were degraded
upon treatment with thalidomide, lenalidomide
or pomalidomide. While they found several pro-
teins that were degraded by one or two of these
drugs, they found only one protein that was
degraded by all three: this was a transcription
factor called SALL4. SALL4 behaved like other
canonical substrates of thalidomide and the
CUL4CRBN complex, with the first two zinc fin-
gers being essential for the complex to recog-
nize SALL4 when the drug is present. Moreover,
the mutation of a glycine residue in one of the
zinc-finger transcription factors was sufficient to
disrupt this drug-induced association
(Petzold et al., 2016).
Multiple observations suggest that identifying
SALL4 as a substrate for the CUL4CRBN complex
is an important step on the road to understand-
ing how thalidomide triggers phocomelia. First,
SALL4 drives limb development in metazoan
organisms (Koshiba-Takeuchi et al., 2006);
Figure 1A). Moreover, mutations in the gene for
SALL4 cause Duane Radial Ray Syndrome and
Holt-Oram Syndrome, two diseases in which
limbs are deformed: indeed, carriers of these
mutations have been misdiagnosed as victims of
thalidomide (Borozdin et al., 2004;
Kohlhase et al., 2002; Kohlhase et al., 2003).
While heterozygous mutations cause the two
syndromes, homozygous mutations are never
observed in patients, and deleting both alleles is
lethal in mice. Taken together, these observa-
tions imply that partial degradation of SALL4, as
accomplished by thalidomide, could be consis-
tent with life, yet induce phocomelia
(Figure 1B).
It was known that CRBN variants that are sen-
sitive to thalidomide, such as those carried by
monkeys and humans, contain the amino acid
valine at position 388. This is required for sub-
strates to bind to the CUL4CRBN complex in the
presence of the drug, and Donovan et al. show
that, in human CRBN, valine is necessary for
SALL4 to be tagged for degradation by
CUL4CRBN. By contrast, most species resistant to
thalidomide contain the amino acid isoleucine at
this position, which prevents the recruitment of
new substrates to CRBN in presence of the drug
or its derivatives.
However, mice expressing a humanized
CRBN with valine in position 388 do not show
limb defects upon thalidomide treatment.
Accordingly, changing isoleucine to valine in
position 388 in CRBN was not sufficient to
Figure 1. Thalidomide, the transcription factor SALL4 and limb defects. (A) In the absence of an
immunomodulatory drug like thalidomide the CUL4CRBN complex (multiple colors) ’tags’ a substrate (purple) for
degradation by the proteasome (pale blue). SALL4 remains intact during this process and is therefore able to
control the transcriptional activity of target genes to control robust embryonic limb development. (B) The
presence of thalidomide results in SALL4 being tagged for degradation. The subsequent absence of SALL4
prevents the transcription of its target genes and thus likely interferes with limb development, as observed in
thalidomide syndrome. iMiD: immunomodulatory drug.
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induce the degradation of SALL4. There are,
therefore, other differences in the sequences of
SALL4 variants in rodents which protect these
animals from the toxic effects of thalidomide.
Indeed, when Donavan et al. combined human
CRBN with a ‘humanized’ variant of mouse
SALL4 that contained five mutations in the criti-
cal second zinc finger, they observed a degrada-
tion of mouse SALL4 under the effect of the
drug. These results strongly point towards the
degradation of SALL4 having a role in thalido-
mide being toxic for embryos. They also high-
light the challenges involved in using mouse
models to evaluate drug candidates for clinical
use. As such, they exemplify the importance of
understanding drug-target interactions at a
molecular level before introducing new thera-
peutics into the market.
Experiments are now required that will com-
bine the expression of humanized SALL4 and
CRBN in a thalidomide-resistant species, such as
mice. If thalidomide creates defects in limb
development in this model, like it did in way too
many children, it would bring proof that the
degradation of SALL4 leads to phocomelia when
the drug is present. While the destruction of
SALL4 likely contributes to the emergence of
phocomelia, thalidomide and its related com-
pounds also induce the degradation of many
other transcription factors, which raises the pos-
sibility that additional targets might also play a
role in the toxic effects of thalidomide on
embryos. Humanized SALL4-animals might pro-
vide a starting platform to discover these miss-
ing targets, particularly those that are related to
other symptoms such as damage in peripheral
nerves.
Importantly, thalidomide has recently gained
much attention for its use as a proteolysis tar-
geting chimera (PROTAC): a PROTAC is a
small molecule that targets disease-causing
proteins to a complex (such as CUL4CRBN) for
ubiquitylation and degradation
(Churcher, 2018; Sakamoto et al., 2001). Yet,
using PROTACs based on thalidomide runs
into the danger of interfering with limb devel-
opment. Companies are therefore hoping to
find and develop other molecules that recruit
proteins to CUL4CRBN without having toxic
effects on human development. The discovery
of SALL4 as a target for thalidomide sheds
new light on a man-made pharmaceutical
disaster, and may make it possible to use tha-
lidomide more safely.
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